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Abstract 
Sequential spread of TDP43 load in the brain may be a pathological characteristic of 
amyotrophic lateral sclerosis (ALS). Diffusion tensor imaging (DTI) is a magnetic 
resonance imaging (MRI) based marker of this pathological feature. Cognitive deficits 
known to be present in a subset of ALS patients might act as an additional in vivo 
clinical marker of disease spread. 
N=139 patients with ALS were tested with the Edinburgh Cognitive and Behavioural 
ALS screen (ECAS) in addition to DTI brain measures of pathological spread. 
Executive function, memory and disinhibited behaviour were selected for Cognitive-
Staging criteria, as these cognitive functions are attributed to cerebral areas 
analogous to the pattern of MRI markers of TDP43 pathology. ROC curve analyses 
were performed to define cut-off scores for cognitive stages 2 (executive function), 
stage 3 (disinhibited behaviour) and stage 4 (memory), and staging was performed 
according to the cognitive profile subsequently. Associations of Cognitive-Staging 
(stage 2-4) and MRI-Staging measures were determined.  
In total, 77 patients (55%) performed below ROC cut-off scores in either executive 
function or memory or both and / or were reported to have disinhibited behaviour 
which permitted Cognitive-Staging. The cognitive profile of patients with discrete MRI 
stages 2 to 4 correlated significantly with DTI parameters. For those patients with 
cognitive impairment, there was a high congruency between MRI and Cognitive-
Staging with high specificity and sensitivity of executive functions for MRI stage 2, 
disinhibited behaviour for MRI stage 3 and moderate of memory for MRI stage 4.  
Cognitive impairment follows specific patterns in ALS and these patterns can be used 
for Cognitive-Staging with a high specificity compared to MRI-Staging. For the 
individual, cognitive screening is a fast and easy to apply measurement of cerebral 
function giving valuable information in a clinical context. 
 
Keywords: Amyotrophic Lateral Sclerosis, diffusion tensor imaging (DTI), cognition, 
staging, TDP43  
 
Abbreviations: ALS = amyotrophic lateral sclerosis, ALS-FRS-R = ALS functional 
rating scale-revised, DTI = diffusion tensor imaging, FA = fractional anisotropy, FTD 
= fronto-temporal dementia 
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1. Introduction 
There is clear evidence in anatomical post-mortem analyses that intraneuronal 
inclusions show a distinct pattern throughout the brains of patients with amyotrophic 
lateral sclerosis (ALS). These phosphorylated 43kDa TAR DNA-binding protein 
(pTDP-43) inclusions seem to follow a sequential pattern of cortical spread in at least 
four stages (Braak, Brettschneider, and Ludolph AC et al., 2013; Brettschneider, Del 
Tredici, and Toledo et al., 2013). This spread is closely linked to sequential 
propagation of oligodendroglia pathology (Fatima, Tan, and Halliday et al., 2015) and 
changes in the white matter connectome (Schmidt, de Reus, and Scholtens et al., 
2015). Using fractional anisotropy (FA) mapping by diffusion tensor imaging (DTI), 
evidence for an in vivo marker of these pathological stages has been provided 
(Kassubek, Müller, and Del Tredici et al., 2014). About one fourth of ALS cases do 
not consecutively fulfill the DTI criteria of staging and therefore do not allow for 
conclusive in vivo MRI-Staging (Kassubek et al., 2014). Furthermore, given that MRI 
is not available in every clinic for every patient and can be difficult for ALS patients 
with respiratory insufficiency, there is a need to provide additional in vivo measures of 
spreading patterns. There is a missing link between microstructural changes and 
functional loss in ALS. Recently, evidence was provided that oculomotor dysfunction 
is a functional marker of ALS pathology (Gorges, Müller, Lulé et al., 2015). An 
additional functional parameter might be cognitive and behavioural changes which 
are the most common non-motor symptoms in ALS and occur in 30 to 50% of 
patients (Goldstein and Abrahams, 2013; Beeldman, Raaphorst, and Klein Twennaar 
et al., 2015). Behavioural abnormalities are present in up to 30% of patients and 
underlie the diagnosis of fronto-temporal dementia (FTD) in 5-10% of ALS patients 
(Strong, Grace, and Freedman et al., 2009). According to Bak’s and Chandran’s 
(2012) hypothesis, the decline in cognitive domains in ALS should be closely 
associated with disease spread in the motor system (Eisen, Turner, and Lemon et al., 
2013). In fact, executive control, language (Taylor, Brown, and Tsermentseli et al., 
2013) and verbal fluency are reported to be the most common domains affected in 
ALS (Goldstein and Abrahams, 2013). Dysfunction of the memory domain is less 
frequently described (Abrahams, Leigh, and Harvey et al., 2000; Abrahams, Newton, 
and Niven et al. 2014; Raaphorst, de Visser, and Linssen et al., 2010; Lulé, 
Burkhardt, and Abdulla et al., 2015; Wei, Chen, and Zheng et al., 2015). Since 
spread of TDP-43 pathology is associated with neuronal loss, it may be expected to 
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change the profile of cognitive performance mirroring functions of the affected brain 
areas. Therefore, we hypothesized that cognitive impairments in ALS show a distinct 
pattern and may serve as a clinical in vivo staging correlate for sequential spreading 
of DTI measures indicative TDP43 pathology (Kassubek et al., 2014). This study will 
determine 1.) whether there is a distinct pattern of cognitive and behaviour 
impairment which is directly associated with MRI staging, 2) whether this pattern may 
be useful for functional in vivo staging whether Cognitive-Staging is an accurate 
predictor of MRI-Staging. Cognitive-Staging is fast and easy to obtain, therefore, it 
may provide valuable information in clinical routine. 
 
2. Methods 
2.1 Participants 
In total, N=139 patients (55 female) with probable or definite diagnosis of 
amyotrophic lateral sclerosis (ALS) were included in the study. Patients underwent 
standardized clinical-neurological and routine laboratory examinations. They were all 
diagnosed with sporadic ALS by a board-certified neurologist according to the Airlie 
House criteria (Miller, Munsat, and Swash et al., 1999) and revised El Escorial criteria 
(Ludolph, Drory, and Hardiman et al., 2015). N=100 had a predominant spinal onset, 
N=34 a predominantly bulbar onset and N=5 had a mixed onset. Severity of physical 
symptoms were mild to moderate as measured with the revised ALS functional rating 
scale (ALS-FRS-R) (Cedarbaum, Stambler, and Malta et al., 1999) (for detailed 
sample characteristics see table 1).  
 
  mean SD range 
Age 60.9 12.2 19-83 
Education [years] 13.0 3.0 4-23 
Duration since onset [months] 20.4 24.1 2-168 
ALS-FRS-R 39.2 6.4 16-48 
Progression  [48-ALS-FRS/duration in months] 0.8 1.0 0.1-6.5 
Fluency 13.3 5.9 0-22 
Language 24.6 3.6 12-28 
Executive function 35.5 6.8 8-45 
Memory 15.2 4.3 0-23 
Visuospatial function 11.4 1.3 7-19 
ALS specific score 73.7 13.3 32-95 
ALS non-specific score 26.6 4.8 8-35 
Total score 100.3 16.5 41-125 
 
Table 1: Sample characteristics and performance in the Edinburgh Cognitive and 
Behavioral ALS Screen (ECAS) of N=139 ALS patients. 
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None of the participants had signs of any neurological or psychiatric illness (other 
than ALS) or overt dementia as these were exclusion criteria for the study. They were 
all native German speakers. All patients eligible for MRI were consecutively recruited 
from the out- and inpatient clinics of the Department of Neurology at the 
Universitätsklinikum Ulm, Germany. 
The study was approved by the Ethics Committee of the University of Ulm (No. 
19/12) and has been performed in accordance with the ethical standards laid down in 
the 1964 Declaration of Helsinki and its later amendments. All participants gave 
written informed consent to the study according to institutional guidelines. 
 
2.2 Study design 
Patients were screened for cognitive dysfunction as a functional measure of ALS 
pathology by a board certified neuropsychologist within 3 days after MRI scanning. 
All patients received MRI scanning according to a standardized protocol (Kassubek 
et al., 2014). Staging (1-4) was then determined separately for each individual by a) 
cognitive and behaviour impairment (Cognitive-Staging) and b) MRI-DTI (MRI-
Staging). 
 
2.3 Cognitive and Behaviour assessment  
Cognitive and behaviour profile was assessed with the German version of the 
Edinburgh Cognitive and Behavioral ALS Screen (ECAS; Abrahams et al. 2014, Lulé 
et al. 2015; Loose, Burkhardt, and Aho-Oezhan et al., 2016), with subdomains of 
ALS specific cognitive functions including executive function, language and verbal 
fluency and non-ALS specific functions of memory and visuospatial perception. 
Maximum total ECAS score is 136 with decreasing score indicating lower cognitive 
performance (table 1). The test has been validated against extensive cognitive 
assessment with good sensitivity and specificity to cognitive dysfunction in ALS 
(Niven, Newton, and Foley et al., 2015; Lulé et al., 2014). 
 
Primary caregivers (all 1st degree family members; N=89) reported behavioural 
changes according to criteria of the ECAS behavioural interview. In total, N=28 (31%) 
presented with changes in behaviour (in at least one domain) with N=9 with 
disinhibited behaviour, N=16 with apathy, N=6 with loss of empathy and social 
interest, N=6 with repetitive behaviour, and N=6 with hyperorality. In total, N=38 were 
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classified as ALSci and N=20 as ALSbi according to the revised Strong criteria 
(Strong, Abrahams, and Goldstein et al., 2017). 
None of the patients presented with evidence of psychosis. 
 
2.4 Theory of Cognitive-Staging  
ECAS cognitive domains of interest were selected according to regional association 
of dysfunction and proposed ALS stages (Braak et al., 2013; figure 1; see also 
graphical abstract). In stage 1 where primary motor areas and the corticospinal tract 
of the cortex are affected, we did not expect impairments in cognition or behaviour. 
Those patients without any cognitive deficits were defined as cognitive stage 1. In 
stage 2, the pathological process in the motor cortex also expands into contiguous 
portions of the premotor and prefrontal regions (Braak et al., 2013; Brettschneider et 
al., 2013). The association between damage in prefrontal regions, in particular the 
dorsal part of the middle prefrontal cortex, and cognition is well established 
(Abrahams et al., 2014; Lillo, Savage, and Mioshi et al., 2012). Cognitive domains 
such as executive control (including verbal fluency as a measure of executive control) 
specifically attributed to structures involved in stage 2 including the dorsal part of the 
middle frontal cortex are associated with reduced cortical activity (Goldstein, 
Newsom-Davis, and Bryant et al., 2011; Witiuk, Fernandez-Ruiz, and McKee et al., 
2014; Abrahams, Goldstein, and Simmons et al., 2004) and reduced white matter 
integrity in ALS (Pettit, Bastin, and Smith et al., 2013) in the respective area. 
Therefore, executive control may serve as marker for pathological stage 2. 
During pathological ALS stage 3, involvement of prefrontal regions progresses to 
more anterior, ventromedial and orbital regions of the frontal cortex such as the gyrus 
rectus and orbitofrontal areas (Brettschneider et al., 2013). Among others, these 
areas are linked to inhibition of socially inappropriate behaviour also known to be 
involved in some ALS patients (Abrahams et al., 2014). Therefore, abnormal 
disinhibited behaviour may be attributed to cortical dysfunction in orbitofrontal cortex.   
In pathological stage 4, hippocampal areas are involved and memory dysfunction in 
ALS has been attributed to structural alterations in these areas (Takeda, Uchihara, 
and Mochizuki et al., 2007; Abdullah, Machts, and Kaufmann et al., 2014; Stoppel, 
Vielhaber, and Eckart et al., 2014). Therefore, measures of memory may serve as 
marker of ALS pathology for stage 4.  
 
7 
 
 
 
Figure 1: Scheme of pathological involvement of either structure (upper part: 
measures of DTI and measures of TDP43 pathology) and function (lower part: 
measures of cognition). All measures may serve as markers of the four pathological 
stages in ALS according to Braak and colleagues (2013). 
 
2.5 Factors associated with cognitive performance 
To see how genotypes were associated with Cognitive-Staging, blood samples were 
derived and genotyped for N=70 patients for which N=4 were positive for C9orf72 
mutations and N=1 was positive for SOD mutations (for detailed protocol see 
Diekstra, Van Deerlin, and van Swieten et al. 2014).  
 
2.6 MRI  
Patients received staging through in vivo diffusion tensor imaging (DTI) markers of 
ALS pathology (Kassubek et al., 2014) according to the post-mortem staging theory 
of ALS by Brettschneider and Braak (Brettschneider et al., 2013).  
For N=99 patients, MRI data were acquired on a 1.5 T clinical scanner (Magnetom 
Symphony, Siemens Medical), the other 40 patients were investigated on a 3.0 T 
head scanner (Allegra, Siemens Medical).  
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The scanning protocol for 1.5T was as follows: 2 x 31 gradient directions, including 
two b = 0 gradient directions, 64 slices, 64 x 64 pixels, slice thickness 3.0 mm, in-
plane pixel size 3.3 mm x 3.3 mm, echo time 28 ms, repetition time 3080 ms, b = 
1000 s/mm2. The scanning protocol for 3T was as follows: 49 gradient directions, 
one b = 0 gradient direction, 52 slices, 96 x 128 pixels, slice thickness 2.2 mm, in-
plane pixel size 2.2 mm x 2.2 mm, echo time 85 ms, repetition time 7600 ms, b = 
1000 s/mm2. For further details see the work of Kassubek and colleagues (2014).  
 
2.7 MRI - Staging 
The DTI analysis software Tensor Imaging and Fiber Tracking (TIFT; Müller, Unrath, 
and Ludolph et al., 2007) was used for post processing and statistical analysis 
according to Kassubek and colleagues (2014). Fractional anisotropy (FA) values for 
reference areas were calculated: for DTI stage 1, FA values of corticospinal tract 
(CST) were determined. For DTI stage 2, FA values in pontine and rubral tract were 
used as reference and for DTI stage 3 striatal paths. For reference, FA values of 
tractus opticus were defined. Overall, 75% of the patients included in the study 
consecutively fulfilled the DTI criteria of staging (i.e. conclusive stage 2 only if criteria 
for stage 1 and stage 2 are fulfilled), whereas the remaining 25% did not allow for 
conclusive in vivo MRI-Staging (called “undefined”; Kassubek et al., 2014).  
 
2.8 Statistics 
All analyses were performed using IBM® SPSS version 21.0 except for definition of 
cut-off points in ROC analyses which were defined with R Statistical Computing 
software version 3.1.3. A priori, data were analyzed for normal distribution using the 
Kolmogorov-Smirnov test. Following, non-parametric tests and Z transformation were 
performed.  
ROC-Analyses were performed for definition of cut-off points for abnormality in 
executive function (stage 2) and memory (stage 4). Disinhibition was indicated as 
present or not. 
Raw data of cognitive function was Z transformed with Fisher transformation. 
Kendall-Tau correlation analyses were performed for association of Z transformed 
cognitive raw-scores of all ECAS subdomains, subtests and FA DTI values and 
between MRI-Staging and Cognitive-Staging. Differences in cognitive parameters 
between DTI stages and cognitive deficits and between those with Cognitive-Staging 
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vs. those without and demographics (age, education) / clinical phenotypes (ALS-FRS, 
region of onset, disease duration, progression) were determined with Mann-Whitney 
U-Test. Chi² analysis was performed for Cognitive-Staging and MRI-Stages, and 
Cognitive-Staging and presence of genetic mutation (C9orf72, SOD). Sensitivity and 
specificity of Cognitive-Staging for MRI stages 2 to 4 were determined. All analyses 
were two-sided and the significance level was adjusted at p=0.05. 
 
3. Results  
3.1 Association of cognitive scores with DTI FA values for MRI-Staging  
Cognitive scores on executive function correlated significantly with the FA values in 
structures associated with MRI stage 1 to 4. Memory correlated significantly with the 
FA values in structures indicating MRI stage 1, 2 and 4 but not with stage 3. Other 
cognitive functions known to be involved in ALS such as verbal fluency (correlation 
with DTI FA measures 2 to 4), language (no correlation with any DTI FA measure) or 
visuospatial function (correlation with DTI FA measures 2 only) similar to subtests in 
the ECAS (supplement table) did not provide any additional information for Cognitive-
Staging.  
Neither cognitive dysfunction correlated with the tractus opticus as reference 
structure (table 2). 
DTI stages tract for DTI 
executive 
function memory 
fluency visuospatial Language 
stage 1 corticospinal tract 0.005 0.05 n.s. n.s. n.s. 
stage 2 pontine tract 0.003 n.s. 0.008 0.05 n.s. 
  rubral tract 0.002 0.008 0.029 0.014 n.s. 
stage 3 striatal path 0.02 n.s. 0.005 n.s. n.s. 
stage 4 perforant path 0.04 0.01 0.007 n.s. n.s. 
reference tractus opticus n.s. n.s. n.s. n.s. n.s. 
 
Table 2: Association of FA values in structures used for MRI-Staging and Z-
transformed scores of performance in cognitive ECAS subdomains including domains 
used for Cognitive-Staging (highlighted in green; Kendall-Tau correlation). 
 
Mean Z scores of executive function (r=-0.15 p=0.5) and memory (Kendall-Tau 
correlation r=-0.16 p=0.04) were significantly associated with MRI stages (Figure 2). 
A between group comparison between those in MRI stage 1 to those in MRI stage 2 
or higher revealed significant differences in executive function (Mann-Whitney-U test 
p=0.004) and memory score (Mann-Whitney-U test p=0.03).  
10 
 
Memory was different between groups with MRI stage 4 compared to MRI stage 3 or 
lower (Mann-Whitney-U test p=0.08), but this difference did not reach significance. 
 
 
Figure 2: Association of Z transformed raw scores in cognitive subdomains 
(executive, blue, and memory function, green, in ECAS) and MRI stages 1 to 4 
according to DTI parameters (Kassubek et al., 2014); Kendall-Tau correlation. 
 
 
3.2 Cognitive-Staging  
Cut-offs in cognitive performance in ECAS subdomains for executive function and 
memory were defined according to ROC-analysis as following. For cognitive ROC 
analysis separating MRI stage 2 from the other stages, executive function was a 
significant predictor with p=0.04 and a cut-off point of ≤ 35 was defined. For cognitive 
ROC analysis separating MRI stage 3 from the other stages, memory was a 
significant predictor with p=0.03 and a cut-off point of ≤ 14 (ROC curves see 
supplement) was determined. To separate MRI stage 3 from other stages with 
regards to cognitive performance, disinhibited behaviour was regarded as either 
present or not and cut-off point was defined as presence of disinhibited behaviour. 
 
In total, cognitive and behavioural scores indicated Cognitive-Staging ≥ 2 in N=77 
patients (55%) whereas N=62 had no cognitive and / or behavioural impairment and 
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provided evidence for cognitive stage 1. . N=75 (53%) had impairment in cognitive 
functions or combined with behavioural impairment and N=2 had changes in 
behaviour only. N=53 were impaired in the executive domain, N=53 in the memory 
domain and N=31 in both domains. Of those N=9 with disinhibited behavior, N=7 also 
had deficits in executive and/or memory domains and N=2 patients were reported to 
have disinhibited behavior only, one of them with involuntary emotion expression 
disorder (IEED). According to Cognitive-Staging criteria, all patients below cognitive 
ROC cut-off points provided evidence for Cognitive stage 2 or higher, with executive 
scores below cut-off score indicating Cognitive stage 2, disinhibited behavior 
indicating Cognitive stage 3 and reduced memory scores indicating Cognitive stage 4 
according to a priori hypothesis mentioned above and ROC analysis.  
 
Figure 3: Scheme of cognitive and behavioural impairments critical for Cognitive 
Staging in the study cohort of N=139 patients.  
 
 
3.3 Association between Cognitive- and MRI-Staging 
All N=77 with cognitive stage 2 or higher also had an MRI stage of 2 or higher except 
the patient with IEED who had MRI stage 1. Those with MRI stage 1 had no cognitive 
impairment and received Cognitive-Stage 1, whereas those with MRI stage 2 or 
higher were more likely to have cognitive impairment in the executive (Chi²=9.59 df=3 
p=0.022) or memory domain (Chi²=11.75 df=3 p=0.008).  
 
For those patients with cognitive deficits, Cognitive-Staging was very specific for 
MRI-Staging: all patients with cognitive dysfunction in executive domain had an MRI 
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stage of at least 2 (100% specificity and sensitivity for stage 2). All patients with 
disinhibited behavior (except the one patient with IEED) had an MRI stage of 3 or 
higher (95% specificity and 100% sensitivity for stage 3). Patients with additional 
memory deficits were more likely to have MRI stage 4 (52% specificity and 55% 
sensitivity for stage 4).  
 
Of those N=35 who had no conclusive MRI-Staging (25%), N=18 patients received 
Cognitive-Staging ≥2 and N=17 (12%) received cognitive staging 1. 
  
 
 
3.4 Association of clinical phenotypes and cognitive impairment 
Compared to those with cognitive-Staging ≥2, those with no cognitive impairment and 
therefore with Cognitive-Stage 1 were younger (mean age 57.1 vs. 66.1 years; Mann-
Whitney-U-Test p<0.001), better educated (mean education 13.7 vs. 11.9 years; 
Mann-Whitney-U-Test p<0.001), and  they were less physically impaired (mean ALS-
FRS 40.3 vs. 37.5; Mann-Whitney-U-Test p=0.04) but there was no difference for 
gender (Chi²=1.3 df=2 p=0.5), region of onset, disease duration nor progression of 
the disease (Mann-Whitney-U-Test all p=0.05).  
 
Those N=4 patients with C9orf72 mutation were either Cognitive-Stage 3 (N=1) or 4 
(N=4) but never Cognitive-Stage ≤ 2 compared to those tested negative for C9orf72 
(N=65; Chi²=21.1 df=6 p=0.002). The patient with SOD mutation presented with no 
cognitive deficits. 
 
 
 
4. Discussion 
The study provides evidence for a distinct pattern of cognitive and behavioural 
alterations in ALS patients consistent with patterns of pathological cerebral 
involvement in ALS (Brettschneider et al., 2013). Cognitive and behavioural deficits 
might be similarly used as in vivo functional markers of ALS pathology, allowing 
Cognitive-Staging for stages 1-4. These cognitive measures were highly associated 
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with DTI parameters used for MRI-based in vivo staging, providing additional 
evidence for a functional measure of pathological patterns in ALS such as it has been 
provided for oculomotor changes (Gorges et al., 2015). For Cognitive-Staging, 
impairment in executive function attributed to prefrontal cortex was highly specific for 
MRI stage 2, disinhibited behavior indicating possible orbitofrontal involvement was 
highly specific for MRI stage 3 and memory dysfunction attributed to 
parahippocampal areas was specific for MRI stage 4 although only in a poor range. 
Other cognitive functions such as verbal fluency or language functions known to be 
involved in ALS (Hervieu-Bègue et al., 2016; Grossman, 2008; Davies et al., 2005) 
did not provide any additional information for Cognitive-Staging. Verbal fluency is an 
executive function providing similar Cognitive-Staging information as the executive 
function score. Language is closely related to motor function and possibly degrades 
much earlier and more closely with bulbar involvement (“What fires together dies 
together”; Bak and Chandran, 2012) which is not fully represented by the DTI FA 
Staging system. Cognitive-Staging provides highly specific clues for in vivo staging in 
ALS complementary to MRI in those patients with cognitive deficits. Major advantage 
is that Cognitive-Staging can be acquired in clinic within 20-25 minutes with low strain 
for the patient and in ALS patients with breathing difficulties unable to perform an 
MRI scan.  
 
4.1 Cerebral involvement in ALS 
Clinical phenotypes of cognitive functions in ALS are diverse (Strong, Grace, and 
Freedman et al., 2009; Bak, 2010) which is further supported by the current data. In 
the literature, there are inconclusive results with regards to the progressive nature of 
cognitive deficits in ALS (Schreiber, Gaigalat, Wiedemuth-Catrinescu et al., 2005), 
possibly explained by heterogeneity of the cognitive pattern within cross-sectional 
comparisons. In a subset of ALS patients, cognitive deficits become more prominent 
over time (Robinson, Lacey, and Grugan et al., 2006) and patients with early onset of 
cognitive impairment show a high probability of progressive nature of cognitive 
dysfunction (Elamin, Bede, and Byrne et al., 2013). Analogous to the spreading 
nature of structural changes of TDP43 and DTI alterations (Braak et al., 2013; 
Kassubek et al., 2014) frequency of functional changes might also increase in the 
course of ALS. The current data suggest that cognitive performance correlates with 
structural disease pathology, providing an indirect link between clinical alterations 
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and structural changes in DTI. The increased involvement of different cognitive 
domains in the course of ALS extends our understanding of an increased impairment 
in one cognitive domain in the course of ALS pathology (Robinson et al., 2006).  
 
4.2 Association of cognition and clinical features 
The current study provides evidence for the association of anatomical (Braak et al., 
2013) and clinical stages in ALS (Balendra, Jones, and Jivraj et al., 2014), further 
supporting previous findings on the association of clinical phenotypes and 
pathological TDP43 spreading (Tan, Kril, and Fatima et al., 2015). Incidence of 
cognitive deficits has been regarded in the context of clinical parameters such as 
survival and respiratory function (Beeldman, Raaphorst, and Klein Twennaar et al., 
2015). In the current study, physical function was more advanced in patients with 
cognitive deficits compared to those without, providing possible evidence for 
progressive nature of cognition; however, in a cross sectional approach only.  
Furthermore, we provide additional evidence that age and education might be a 
protective factor for cognitive decline as it was previously shown for dementia 
(Terrera, Minett, and Brayne et al., 2014). Finally, C9orf72 mutations were associated 
with Cognitive-Staging providing further support for a pathological link of this mutation 
and cognition in ALS and FTD patients (Montuschi, Iazzolino, and Calvo et al., 2015). 
 
Providing that all demographic and affective parameters are carefully controlled for, 
cognitive and behavioural measures are highly specific for MRI stages in ALS, 
indicating TDP pathology in prefrontal, orbitofrontal and parahippocampal areas but 
in the subset of patients with cognitive alterations only. Memory was only poorly 
specific for parahippocampal involvement. For the memory task there is not only 
temporal but also prefrontal cortex involvement supported by the fact that raw scores 
of memory correlated with DTI parameters in pontine and rubral tract indicative of 
MRI stage 2. For those patients with a possible FTD phenotype, temporal 
involvement attributed to memory function may be more specific for Cognitive-Stage 
2 (Brettschneider et al., 2014). Taken together, the majority of 88% received either 
MRI- or Cognitive-Staging or both. Those 12% with no in vivo-staging were rather 
young and therefore, structural (i.e. TDP pathology) and functional changes (possibly 
due to compensatory processes in young age; Terrera et al., 2014) might show an 
ALS-untypical pattern of propagation.  
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4.3 Limitations 
In total, 45% of all patients present with no cognitive deficits (Phukan, Elamin, and 
Bede et al., 2012; Beeldman et al., 2010) and evidence for Cognitive-Stage 1 can be 
given only. This lack of cognitive impairment might be either explained by cognitive 
reserve and compensatory processes in some cases (Perquin, Diederich, and 
Pastore et al., 2015) with e.g. high education as protective factor or it might be 
attributed to a non-cognitive clinical phenotype of ALS, emphasizing the 
heterogeneity in ALS. Furthermore, staging 3 using behavioural alterations showed a 
rather poor performance for Cognitive-Staging and needs further validation in future 
studies. 
A major limitation is that the current cross-sectional study does not provide proof of 
progressive nature of Cognitive-Staging within an individual so that future longitudinal 
studies are needed.  
Furthermore, for the MRI data collection different systems were used but Mueller and 
colleagues have provided evidence that different MRI data collection systems provide 
similar results with regard to DTI measures for ALS Staging (Kassubek et al., 2014). 
Finally, DTI and cognitive screening are two techniques which measure completely 
different parameters. DTI is a measure of structural alterations in axons of white 
matter while cognitive screening is a functional measure of cognitive performance 
known to be dependent on correct functioning within specific cortical networks. Both 
measures have a very high congruency. However, DTI and cognitive measures at the 
very best describe different aspects of the same pathological mechanism in ALS.   
 
4.4 Conclusion 
The current study provides evidence that frequency and pattern of functional 
measures of cortical performance such as cognition and behaviour show a distinct 
pattern in ALS which might be useful for in vivo Cognitive-Staging in ALS. Cognitive 
measures were closely linked to structural alterations of DTI MRI signals indicative of 
TDP43 pathology in ALS. Consistency of MRI staging and cognitive screening 
parameters provides suggestive evidence that both methods might add 
complementary in vivo information for pathological staging according to Braak et al. 
(2013) in the subset of cognitively impaired patients but longitudinal studies are 
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warranted to highlight the progressive nature of the hereby described pathology 
pattern.    
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